MTOR inhibitor-based combination therapies for pancreatic cancer

BACKGROUND: Although the mechanistic target of rapamycin (MTOR) kinase, included in the mTORC1 and mTORC2 signalling hubs, has been demonstrated to be active in a significant fraction of patients with pancreatic ductal adenocarcinoma (PDAC), the value of the kinase as a therapeutic target needs furt...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Zonera, Schneeweis, Christian, Wirth, Matthias, Veltkamp, Christian, Dantes, Zahra, Feuerecker, Benedikt, Ceyhan, Güralp O, Knauer, Shirley K, Weichert, Wilko, Schmid, Roland M, Stauber, Roland, Arlt, Alexander, Krämer, Oliver H, Rad, Roland, Reichert, Maximilian, Saur, Dieter, Schneider, Günter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808033/
https://www.ncbi.nlm.nih.gov/pubmed/29384525
http://dx.doi.org/10.1038/bjc.2017.421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808033/
https://www.ncbi.nlm.nih.gov/pubmed/29384525
http://dx.doi.org/10.1038/bjc.2017.421

Ejemplares similares